Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07145411 · ClinicalTrials.gov registry record

HPC Offered for PRESERVE Expansion

A clinical trial of Bone Marrow Transplant (BMT), sponsored by Ossium Health.

Recruiting
Registry status
10
Enrollment target
4
Study locations

NCT07145411: Recruiting study of Bone Marrow Transplant (BMT), sponsored by Ossium Health.

NCT07145411 is a study of Bone Marrow Transplant (BMT) that is actively recruiting participants, run by Ossium Health. The registered enrollment target is 10 participants. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07145411, a study of Bone Marrow Transplant (BMT), is actively recruiting participants, sponsored by Ossium Health.

RECRUITING
Registry status
10 participants
Enrollment target
4
Study locations

Study Summary

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Primary Outcome

1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)

Interventions

  • OTHER Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)

Study Locations (4)

Alabama

  • University of Alabama, Birmingham - Birmingham

Michigan

  • Henry Ford Health - Detroit

Ohio

  • The Ohio State University Medical Center - Columbus

Tennessee

  • Tristar Centennial Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-06-27
Est. Completion 2029-08
Ossium Health

2 total trials

What NCT07145411 shows while recruiting

NCT07145411 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.

The record links to 1 condition, with Bone Marrow Transplant (BMT) appearing as the primary indexed condition, and to 1 intervention - of which Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors) is the first listed.

NCT07145411 reports a single indexed study location in Alabama, Michigan, Ohio.

Frequently Asked Questions

What is clinical trial NCT07145411 about?

NCT07145411 is a clinical study titled "HPC Offered for PRESERVE Expansion". Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

What is the current status of trial NCT07145411?

This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2024-06-27. Estimated completion is 2029-08.

What conditions does trial NCT07145411 study?

This clinical trial studies the following conditions: Bone Marrow Transplant (BMT).

What interventions are being tested in trial NCT07145411?

The interventions under investigation include: Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors) (OTHER).

Who is sponsoring clinical trial NCT07145411?

This trial is sponsored by Ossium Health, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07145411 being conducted?

This trial has 4 study locations across Alabama, Michigan, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bone Marrow Transplant (BMT)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07145411, the US trial registry maintained by the National Library of Medicine. NCT07145411 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.